Evidence map›Paper›PMID 42646508›Full record

ArticleMethods and protocols2026

Single Radial Immunodiffusion (SRID) Assay for Quantitative Determination of Recombinant SOD Protein in a Brucellosis Vaccine Candidate: Method Development and Validation.

Gulnur Nakhanova, Olga Chervyakova, Kamshat Shorayeva, Aigerim Zhakypbek, Sabina Moldagulova, Aknur Ulankyzy, Alisher Omurtay, Yeraly Shayakhmetov, Temirlan Baiseit, Zharkinay Absatova and 12 more

Abstract read
In one paragraph

Article in Methods and protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Gulnur NakhanovaResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Olga ChervyakovaResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.ORCID 0000-0002-7954-6246
Kamshat ShorayevaResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Aigerim ZhakypbekResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Sabina MoldagulovaResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Aknur UlankyzyResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Alisher OmurtayResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Yeraly ShayakhmetovResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Temirlan BaiseitResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Zharkinay AbsatovaResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Aisha IssabekResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.ORCID 0000-0002-5623-7571
Gaukhar ShynybekovaResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.ORCID 0000-0002-6976-1540
Sandugash SadikaliyevaResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Aziz NakhanovResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.ORCID 0000-0002-6593-0271
Kuanysh JekebekovResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.
Ainar KossylganovaSchool of Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0009-0004-2902-1777
Karlygash ZhaparkulovaSchool of Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.
Assem KalykovaSchool of Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0000-0002-7699-4561
Tolkyn BekezhanovaSchool of Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0000-0002-6088-5002
Albina AtakanovaSchool of Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.
Zakir YershebulovLimited Liability Partnership "OtarBioPharm", QazBioPharm National Holding JSC, Gvardeiskiy 080409, Kazakhstan.
Kuandyk ZhugunissovResearch Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan.ORCID 0000-0003-4238-5116

Funding

Ministry of Health of the Republic of Kazakhstan IRN BR25293294
6 · The paper itself

Abstract

Recombinant superoxide dismutase (SOD) protein is a promising antigen candidate for brucellosis vaccines, and its quantitative determination is essential for vaccine quality control, standardization, and regulatory compliance. Although enzyme-linked immunosorbent assay (ELISA) is widely used for antigen quantification, its application to vaccine formulations may be limited due to chemical modifications of antigenic determinants occurring during detoxification and adjuvantation processes. Therefore, alternative analytical methods, such as single radial immunodiffusion (SRID), which enable direct antigen quantification independent of antigenic determinant modifications, represent valuable tools for vaccine analysis. The aim of this study was to develop and validate a single radial immunodiffusion (SRID) assay for the quantitative determination of recombinant SOD protein and to obtain hyperimmune sera in sheep. Sheep were immunized with recombinant SOD protein formulated with aluminum hydroxide or AddaS03 adjuvants. Antibody responses were evaluated using agar gel immunodiffusion (AGID) and enzyme-linked immunosorbent assay (ELISA). Immunization with aluminum hydroxide induced higher antibody titers than AddaS03. By day 42, ELISA titers reached 1:25,600 in the aluminum hydroxide group compared with 1:3200 in the AddaS03 group. The obtained hyperimmune sera were used for SRID assay development. The optimized SRID assay demonstrated high reproducibility and specificity, with no cross-reactivity against unrelated proteins. A linear relationship was observed between the square of the precipitation ring diameter (D

Indexed as

brucellosismethod validationrecombinant proteinssingle radial immunodiffusionvaccine quality control

Identifiers

PMID42646508
PMCPMC13515976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.